Nucleai
Founded Year
2018Stage
Series B - II | AliveTotal Raised
$58.5MLast Raised
$14M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-79 points in the past 30 days
About Nucleai
Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.
Loading...
ESPs containing Nucleai
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for oncology diagnostics market digitizes and obtains high-resolution images of cancerous tissue samples. These digital images can be easily stored, shared, and accessed remotely by pathologists, enabling more efficient collaboration and second opinions. The market includes various hardware and software solutions for scanning, storing, analyzing, and managing digital patholog…
Nucleai named as Challenger among 15 other companies, including Microsoft, Roche, and NVIDIA.
Nucleai's Products & Differentiators
Spatial Biomarker Quantifier
Nucleai's spatial biomarker quantifier detects and quantifies biomarkers from pathology images (IHC, multiplex) to more accurately and objectively match patients to the right therapy. This can range from quantifying known biomarker assays such as PDL1, PD1, HER2, etc. to quantifying robust multiplex assays (up to 12-plex). Nucleai also leverages this product to optimize inclusion/exclusion thresholds for IHC and multiplex assays, (i.e. setting a new threshold for PDL1 which produces better response to therapy). Nucleai is currently deploying this product across 5 pharmacos and 6 clinical trials, for RUO, and is further developing several of these assays for prospective patient selection.
Loading...
Research containing Nucleai
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Nucleai in 2 CB Insights research briefs, most recently on Jun 27, 2024.
Aug 10, 2023
The oncology tech market mapExpert Collections containing Nucleai
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nucleai is included in 3 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
571 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence (AI)
20,628 items
Nucleai Patents
Nucleai has filed 3 patents.
The 3 most popular patent topics include:
- 3d imaging
- artificial neural networks
- autoimmune diseases
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/2/2020 | 1/14/2025 | Clusters of differentiation, Transcription factors, Immune system, Immunology, Autoimmune diseases | Grant |
Application Date | 7/2/2020 |
|---|---|
Grant Date | 1/14/2025 |
Title | |
Related Topics | Clusters of differentiation, Transcription factors, Immune system, Immunology, Autoimmune diseases |
Status | Grant |
Latest Nucleai News
Oct 19, 2025
, the AI-powered spatial biology company, has once again been named among the Top 10 Spatial Biology Companies of 2025 by Genetic Engineering & Biotechnology News (GEN) , marking the third consecutive year the company has earned this distinction. The list honors the innovators shaping the rapidly evolving field of spatial biology, a discipline that integrates biology, imaging, and data science to understand tissue-level interactions with unprecedented precision. Nucleai stands out for its unique approach to making spatial biology more actionable for scientists and clinicians, bridging the gap between research and real-world medical impact. AI-Powered Breakthroughs in Biomarker Discovery This recognition comes as Nucleai launches new deep learning and object-detection (OD)-based biomarker scoring technologies, empowering researchers and pharmaceutical partners to quantify spatial biomarkers and accelerate the development of precision therapies. By combining advanced AI models with multi-modal spatial data, Nucleai enables deeper insights into the tumor microenvironment, immune interactions, and treatment response. These are critical factors in the design of next-generation oncology drugs and diagnostic tools. “ We're proud to see Nucleai recognized once again among the global leaders advancing spatial biology, ” said Avi Veidman, Nucleai's CEO. “ Their technology is transforming how spatial data is used — from discovery to diagnostics — bringing precision medicine closer to everyday clinical practice. ” Bridging Discovery, Pharma, and Diagnostics As the only company on the GEN list building an AI-powered operating system for multimodal spatial data, Nucleai continues to redefine how the life sciences industry leverages data to drive clinical breakthroughs. The company joins global leaders such as Bio-Techne, Bruker, 10x Genomics, and Standard BioTools , a testament to its technological excellence and consistent innovation. Learn More See the full list and feature on GEN Top 10 Spatial Biology Companies of 2025
Nucleai Frequently Asked Questions (FAQ)
When was Nucleai founded?
Nucleai was founded in 2018.
Where is Nucleai's headquarters?
Nucleai's headquarters is located at 400 North Aberdeen Street, Chicago.
What is Nucleai's latest funding round?
Nucleai's latest funding round is Series B - II.
How much did Nucleai raise?
Nucleai raised a total of $58.5M.
Who are the investors of Nucleai?
Investors of Nucleai include Grove Ventures, Fosun RZ Capital, Vertex Ventures, Debiopharm Investment, Section 32 and 12 more.
Who are Nucleai's competitors?
Competitors of Nucleai include Paige and 4 more.
What products does Nucleai offer?
Nucleai's products include Spatial Biomarker Quantifier and 2 more.
Who are Nucleai's customers?
Customers of Nucleai include Merck EMD Serono and Debiopharm.
Loading...
Compare Nucleai to Competitors
Aignostics specializes in AI-powered precision medicine, focusing on the biopharmaceutical industry. The company offers insights by analyzing complex biomedical data, including histopathology, omics, and clinical outcomes, to support drug development and improve patient outcomes. It serves the biopharma sector with solutions for target identification, translational research, trials, and companion diagnostics. It was founded in 2018 and is based in Berlin, Germany.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.
BioAI focuses on advancing precision medicine through multimodal artificial intelligence within the biopharmaceutical sector. The company offers artificial intelligence (AI) driven services for biomarker discovery, drug target identification, and clinical data sourcing, aiming to enhance drug discovery and clinical development processes. BioAI primarily serves the biopharma industry, leveraging AI to improve disease diagnosis and predict patient responses to therapies. It was founded in 2020 and is based in Manchester, New Hampshire.
Ellogon.AI provides a solution named EIDOS, which utilizes deep learning technology to assist medical experts in selecting suitable patients for immunotherapy by quantifying relevant biomarkers from histopathology images. The company operates within the healthcare sector, specifically targeting medical professionals involved in cancer treatment and research. It was founded in 2019 and is based in Amsterdam, Netherlands.
Stratipath specializes in AI-based precision diagnostics within the healthcare sector, focusing on cancer treatment decision support. The company offers cloud-based SaaS solutions that leverage deep learning technologies to provide risk profiling of tumors, particularly for breast cancer. Stratipath's services are utilized by healthcare providers, including oncology clinics and pathology labs, to enhance the diagnostic process. It is based in Sweden.
biomy provides AI analysis software for cancer microenvironments. The company offers AI-based spatial analysis technology that aids in understanding the tumor microenvironment, predicting patient prognosis, and suggesting appropriate cancer treatments. It serves the biopharma and clinical laboratory sectors. It was founded in 2019 and is based in Tokyo, Japan.
Loading...